Ірина Давиденко

2.6k citations
33 papers · 1.7k · 1 hit paper · h-index 16

Impact in

  • Otorhinolaryngology top 1%
    • Head and Neck Cancer Studies
  • Hepatology top 2%
    • Hepatocellular Carcinoma Treatment and Prognosis
    • Liver physiology and pathology

Papers in

  • Oncology 17
    • Colorectal Cancer Treatments and Studies 10
    • Pancreatic and Hepatic Oncology Research 7
  • Pulmonary and Respiratory Medicine 15
    • Lung Cancer Treatments and Mutations 7
    • Gastric Cancer Management and Outcomes 5
Co-authors
Kelly S. Oliner (9 shared papers)Marinela Capanu (2 shared papers)J. Lacava (2 shared papers)Jennifer J. Knox (2 shared papers)Thomas W. T. Leung (2 shared papers)Leonard B. Saltz (2 shared papers)Ghassan K. Abou‐Alfa (2 shared papers)Philip J. Johnson (2 shared papers)
Journals
Journal of Clinical Oncology (11 papers)Annals of Oncology (8 papers)European Journal of Cancer (4 papers)Clinical Cancer Research (2 papers)The Lancet Oncology (2 papers)
Partner nations
United StatesRussiaUnited Kingdom

In The Last Decade

Ірина Давиденко

29 papers receiving 1.6k citations

Ірина Давиденко's Hit Papers

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial 2013 · 337 citations
3370+4+8Years since publication100200300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2013 The Lancet Oncology

Peers

Ірина Давиденко
Comparison fields: 5 of 74
  • Otorhinolaryngology 242
  • Hepatology 408
  • Oncology 656
  • Biological Psychiatry 42
  • Pulmonary and Respiratory Medicine 448
Replace Silvia Mezi with:
Silvia Mezi Italy
Hirofumi Yasui Japan
Feng-Hua Wang China
Changping Wu China
Yoshihiro Nabeya Japan
Carles Pericay Spain
Jean-Marie Ledeine Belgium
Roberto Carmagnani Pestana United States
C. Couteau France
Felix Chu United States
Ірина Давиденко relative to Silvia Mezi Italy Silvia Mezi's profile →
Citations per field
00.5×2×2.9×
Silvia Mezi · 1×
Citations per year

Countries citing papers authored by Ірина Давиденко

Since Specialization
Citations

This map shows the geographic impact of Ірина Давиденко's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ірина Давиденко with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ірина Давиденко more than expected).

Fields of papers citing papers by Ірина Давиденко

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ірина Давиденко. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ірина Давиденко. The network helps show where Ірина Давиденко may publish in the future.

Co-authors

The 25 scholars most cited alongside Ірина Давиденко, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ірина Давиденко Line = papers co-authored together Ірина Давиденко links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
JAMA ·Ghassan K. Abou‐Alfa, Philip J. Johnson, Jennifer J. Knox, Marinela Capanu, Ірина Давиденко, J. Lacava, Thomas W. T. Leung, Bolorsukh Gansukh, Leonard B. Saltz
2010361
2
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
The Lancet Oncology ·Jan B. Vermorken, Jan Stöhlmacher-Williams, Ірина Давиденко, Lisa Licitra, Eric Winquist, Cristian Villanueva, Paolo Foa, Sylvie Rottey, Krzysztof Składowski, Makoto Tahara, Vasant R. Pai, Sandrine Faivre, C. Blajman, Arlene A. Forastiere, B. Stein, Kelly S. Oliner, Zhiying Pan, Bruce Allen Bach
Hit paper breakdown →		2013337
3
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
The Lancet Oncology ·Timothy Iveson, Ross C. Donehower, Ірина Давиденко, S. Tjulandin, Andrzej Deptała, Mark Harrison, S S Nirni, K C Lakshmaiah, Anne Thomas, Yizhou Jiang, Min Zhu, Rui Tang, Abraham Anderson, Sarita Dubey, Kelly S. Oliner, Elwyn Loh
2014226
4
Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.
Journal of Clinical Oncology ·David Cunningham, Niall C. Tebbutt, Ірина Давиденко, André M. Murad, Salah‐Eddin Al‐Batran, David H. Ilson, Sergei Tjulandin, Evgeny Gotovkin, Bogusława Karaszewska, Igor Bondarenko, Mohamedtaki Abdulaziz Tejani, Anghel Adrian Udrea, Mustapha Tehfé, Nigel Baker, Kelly S. Oliner, Yilong Zhang, Tien Hoang, Roger Sidhu, Daniel Virgil Thomas Catenacci
2015123
5
Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Clinical Cancer Research ·Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Ірина Давиденко, Joe Stephenson, Elena Élez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero
201495
6
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
Gynecologic Oncology ·Rebecca Kristeleit, Ірина Давиденко, Vadim Shirinkin, Fatima El-Khouly, Igor Bondarenko, Michael J. Goodheart, В. А. Горбунова, C A Penning, Jack Shi, Xiangdong Liu, Robert Newton, Yufan Zhao, Janet Maleski, Lance Leopold, Russell J. Schilder
201781
7
Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
Clinical Cancer Research ·Josep Tabernero, Rocio García‐Carbonero, James T. Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Ірина Давиденко, Ramón Salazar, Л. Ю. Владимирова, Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, Irina Bulavina, Vanessa Potter, Yu-Lin Chang, Nathalie A. Lokker, Peter J. O’Dwyer
201372
8
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
Annals of Oncology ·Kimberly Blackwell, Vladimir Semiglazov, Dmitriy Krasnozhon, Ірина Давиденко, L. Nelyubina, Roumen Nakov, G. Stiegler, Pritibha Singh, Arnd Schwebig, Simon Krämer, Nadia Harbeck
201566
9
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
International Journal of Gynecological Cancer ·Amit M. Oza, Frédèric Selle, Ірина Давиденко, Jacob Korach, César Mendiola, Patricia Pautier, Ewa Chmielowska, Aristotelis Bamias, Andrea DeCensi, Zanete Zvirbule, Antonio González-Martı́n, Roberto Hegg, Florence Joly, Claudio Zamagni, Angiolo Gadducci, Nicolas Martin, Stephen Robb, Nicoletta Colombo
201655
10
Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Recombinant Human Intestinal Trefoil Factor Oral Spray for Prevention of Oral Mucositis in Patients With Colorectal Cancer Who Are Receiving Fluorouracil-Based Chemotherapy
Journal of Clinical Oncology ·Douglas E. Peterson, Nicholas P. Barker, L. I. Akhmadullina, Irina Rodionova, Н. З. Шерман, Ірина Давиденко, Galina N. Rakovskaya, E. Gotovkin, (unknown), М. В. Копп, Eugeny P. Kulikov, Vladimir Moiseyenko, Joseph M. Gertner, Igor Firsov, Tamara Tuleneva, A. O. Yarosh, Chee-Wai Woon
200954
11
A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses.
Journal of Clinical Oncology ·Cathy Eng, Eric Van Cutsem, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Ірина Давиденко, Kelly S. Oliner, L. Chen, Jing Huang, Ian McCaffery, Elwyn Loh, Dominic Smethurst, Josep Tabernero
201132
12
Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma
Annals of Oncology ·David Propper, Ірина Давиденко, John Bridgewater, Limas Kupčinskas, A. Fittipaldo, Carina Hillenbach, Barbara Klughammer, Michel Ducreux
201426
13
6504 ORAL Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma
European Journal of Cancer ·Timothy Iveson, Ross C. Donehower, Ірина Давиденко, S. Tjulandin, Andrzej Deptała, M. Harrison, Elwyn Loh, Ya Jiang, Kelly S. Oliner, S. Dubey
201123
14
An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM)
Journal of Clinical Oncology ·J. B. Vermorken, J. Stöhlmacher, Ірина Давиденко, Eric Winquist, Lisa Licitra, V. R. Pai, Krzysztof Składowski, C. Blajman, Sandrine Faivre, Jennifer Gansert
200920
15
RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Journal of Clinical Oncology ·David Cunningham, Salah‐Eddin Al‐Batran, Ірина Давиденко, David H. Ilson, André M. Murad, Niall C. Tebbutt, Yizhou Jiang, Elwyn Loh, Sarita Dubey, (unknown)
201317
16
Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial.
Journal of Clinical Oncology ·Jan Stoehlmacher-Williams, Cristian Villanueva, Paolo Foa, Sylvie Rottey, Eric Winquist, Lisa Licitra, Ірина Давиденко, Krzysztof Składowski, Makoto Tahara, Sandrine Faivre, Kelly S. Oliner, Zhiying Pan, Bruce Allen Bach, Jan B. Vermorken
201217
17
Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa, Philip J. Johnson, Jennifer J. Knox, Marinela Capanu, Ірина Давиденко, J. Lacava, Thomas W. T. Leung, Leonard B. Saltz
201312
18
Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment.
Journal of Clinical Oncology ·Elizabeth Poplin, Harpreet Wasan, Lindsey Rolfe, Mitch Raponi, Tone Ikdahl, Igor Bondarenko, Ірина Давиденко, В. Ю. Бондарь, August Garin, Stefan Boeck, Volker Heinemann, Claudio Bassi, T.R. Jeffry Evans, Cynthia Voong, Paramjit Kaur, Jeffrey D. Isaacson, Andrew R. Allen
201310
19
Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Therapy in Patients with Advanced Met-Positive Gastric or Gastroesophageal Junction (G/Gej) Adenocarcinoma
Annals of Oncology ·David Cunningham, S-E. Al-Batran, Ірина Давиденко, David H. Ilson, A.M. Murad, Niall C. Tebbutt, Nigel Baker, Rajul K. Jain, Tien Hoang
20148
20
A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial
European Journal of Cancer ·Josep Tabernero, Rocio García‐Carbonero, C.H. Könne, P J O'Dwyer, Alberto Sobrero, E. Van Cutsem, Oleg Gladkov, Ірина Давиденко, Ramón Salazar, J Cassidy
20117

About Ірина Давиденко

Ірина Давиденко is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hepatology, Cancer Research and Otorhinolaryngology, having authored 33 papers that have together received 1.7k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (10 papers), Pancreatic and Hepatic Oncology Research (7 papers), Lung Cancer Treatments and Mutations (7 papers), Gastric Cancer Management and Outcomes (5 papers), Head and Neck Cancer Studies (4 papers), Ovarian cancer diagnosis and treatment (4 papers), Cancer Research and Treatments (4 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Otorhinolaryngology (242 citations), Hepatology (408 citations), Oncology (656 citations), Biological Psychiatry (42 citations) and Pulmonary and Respiratory Medicine (448 citations). Ірина Давиденко has collaborated with scholars based in United States, Russia and United Kingdom. Frequent co-authors include Kelly S. Oliner, Marinela Capanu, J. Lacava, Jennifer J. Knox, Thomas W. T. Leung, Leonard B. Saltz, Ghassan K. Abou‐Alfa, Philip J. Johnson, Bolorsukh Gansukh and Elwyn Loh. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Clinical Cancer Research and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Silvia MeziBreakdown of academic impact, for papers by Hirofumi YasuiBreakdown of academic impact, for papers by Feng-Hua WangBreakdown of academic impact, for papers by Changping WuBreakdown of academic impact, for papers by Yoshihiro NabeyaBreakdown of academic impact, for papers by Carles PericayBreakdown of academic impact, for papers by Jean-Marie LedeineBreakdown of academic impact, for papers by Roberto Carmagnani PestanaBreakdown of academic impact, for papers by C. CouteauBreakdown of academic impact, for papers by Felix Chu